title: Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand.
abstract: Halofantrine (WR 171,669) hydrochloride was administered orally to 82 patients infected with Plasmodium falciparum malaria on the Thai-Kampuchean border between June 1982 and December 1983 in a randomized double-blind treatment trial which compared the efficacy of halofantrine with that of mefloquine. Halofantrine was curative with oral treatment on a single day in 65% of patients (13/20) who received 1000 mg followed 6 hours later by an additional 500 mg, and in 88% of patients (53/60) who received 500 mg every 6 hours for 3 doses. Mefloquine was curative in 88% of patients (22/25) given a single oral dose of 1000 mg and in 97% of patients (38/39) given a single oral dose of 1500 mg. The difference in cure rates between the 3-dose halofantrine regimen and either of the mefloquine regimens was not significant. The mean parasite clearance time for all regimens ranged from 75 to 84 hours. The mean fever clearance time for all four treatment groups was in the range 50-60 hours, with no significant differences between groups. Post-dosing side-effects in patients treated with halofantrine consisted of nausea, vomiting, abdominal pain and diarrhoea and were not significantly different from those treated with mefloquine. Halofantrine therefore appeared to be of comparable efficacy to mefloquine in the treatment of multidrug-resistant P. falciparum malaria.
authors.forename: E F
authors.initials: EF
authors.lastname: Boudreau
authors.forename: L W
authors.initials: LW
authors.lastname: Pang
authors.forename: K E
authors.initials: KE
authors.lastname: Dixon
authors.forename: H K
authors.initials: HK
authors.lastname: Webster
authors.forename: K
authors.initials: K
authors.lastname: Pavanand
authors.forename: L
authors.initials: L
authors.lastname: Tosingha
authors.forename: P
authors.initials: P
authors.lastname: Somutsakorn
authors.forename: C J
authors.initials: CJ
authors.lastname: Canfield
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D015767:Mefloquine; D008875:Middle Aged; D010616:Phenanthrenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D011897:Random Allocation
chemical_list: D000962:Antimalarials; D010616:Phenanthrenes; D011804:Quinolines; C023768:halofantrine; D015767:Mefloquine